MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

NCT04161898 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-02-18

No results posted yet for this study

Summary

The main objective of this study is to evaluate the efficacy of upadacitinib in combination with a corticosteroid taper regimen compared to placebo in combination with a corticosteroid taper regimen.

Conditions

  • Takayasu Arteritis (TAK)

Interventions

DRUG

Upadacitinib

Upadacitinib will be administered as oral tablet

DRUG

Placebo for Upadacitinib

Placebo for upadacitinib will be administered as oral tablet

DRUG

Prednisolone

Prednisolone will be administered as oral tablet

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-04
Primary Completion
2028-08-31
Completion
2028-08-31
FDA Drug
Yes

Countries

  • Argentina
  • Brazil
  • China
  • Japan
  • South Korea
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161898 on ClinicalTrials.gov